Next Article in Journal
Recent Advances and Future Perspectives in Microbial Phototrophy in Antarctic Sea Ice
Next Article in Special Issue
Strategies to Block HIV Transcription: Focus on Small Molecule Tat Inhibitors
Previous Article in Journal
Improved Cholinergic Transmission is Detrimental to Behavioural Plasticity in Honeybees (Apis mellifera)
Previous Article in Special Issue
Transcriptional Gene Silencing (TGS) via the RNAi Machinery in HIV-1 Infections
Biology 2012, 1(3), 521-541; doi:10.3390/biology1030521
Review

Inhibitors of HIV-1 Reverse Transcriptase—Associated Ribonuclease H Activity

1
, 1,2
, 3
, 2
 and 1,*
Received: 18 August 2012; in revised form: 26 September 2012 / Accepted: 27 September 2012 / Published: 19 October 2012
(This article belongs to the Special Issue Structural and Molecular Biology of HIV)
View Full-Text   |   Download PDF [656 KB, updated 23 October 2012; original version uploaded 19 October 2012]   |   Browse Figures
Abstract: HIV-1 enzyme reverse transcriptase (RT) is a major target for antiviral drug development, with over half of current FDA-approved therapeutics against HIV infection targeting the DNA polymerase activity of this enzyme. HIV-1 RT is a multifunctional enzyme that has RNA and DNA dependent polymerase activity, along with ribonuclease H (RNase H) activity. The latter is responsible for degradation of the viral genomic RNA template during first strand DNA synthesis to allow completion of reverse transcription and the viral dsDNA. While the RNase H activity of RT has been shown to be essential for virus infectivity, all currently used drugs directed at RT inhibit the polymerase activity of the enzyme; none target RNase H. In the last decade, the increasing prevalence of HIV variants resistant to clinically used antiretrovirals has stimulated the search for inhibitors directed at stages of HIV replication different than those targeted by current drugs. HIV RNase H is one such novel target and, over the past few years, significant progress has been made in identifying and characterizing new RNase H inhibitor pharmacophores. In this review we focus mainly on the most potent low micromolar potency compounds, as these provide logical bases for further development. We also discuss why HIV RNase H has been a difficult target for antiretroviral drug development.
Keywords: HIV-1; reverse transcription; ribonuclease H (RNase H); ribonuclease H inhibitor (RNHI) HIV-1; reverse transcription; ribonuclease H (RNase H); ribonuclease H inhibitor (RNHI)
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Export to BibTeX |
EndNote


MDPI and ACS Style

Ilina, T.; LaBarge, K.; Sarafianos, S.G.; Ishima, R.; Parniak, M.A. Inhibitors of HIV-1 Reverse Transcriptase—Associated Ribonuclease H Activity. Biology 2012, 1, 521-541.

AMA Style

Ilina T, LaBarge K, Sarafianos SG, Ishima R, Parniak MA. Inhibitors of HIV-1 Reverse Transcriptase—Associated Ribonuclease H Activity. Biology. 2012; 1(3):521-541.

Chicago/Turabian Style

Ilina, Tatiana; LaBarge, Krystal; Sarafianos, Stefan G.; Ishima, Rieko; Parniak, Michael A. 2012. "Inhibitors of HIV-1 Reverse Transcriptase—Associated Ribonuclease H Activity." Biology 1, no. 3: 521-541.


Biology EISSN 2079-7737 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert